Blincyto 35 mcg lyophilized powder for injection Images
Generic Name: blinatumomab
This medication has been identified as Blincyto 35 mcg lyophilized powder for injection. It is supplied by Amgen Inc.
Blincyto is used in the treatment of Acute Lymphoblastic Leukemia and belongs to the drug class bispecific T-cell engagers (BiTE). Risk cannot be ruled out during pregnancy. Blincyto 35 mcg lyophilized powder for injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication

Blincyto
- Generic Name
- blinatumomab
- Strength
- 35 mcg lyophilized powder for injection
- Availability
- Prescription only
- Drug Class
- Bispecific T-cell engagers (BiTE)
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Amgen Inc.
- National Drug Code (NDC)
- 55513-0160
See also:
Sprycel
Sprycel is used to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Learn about ...
Gleevec
Gleevec is targeted cancer therapy for specific types of leukemia (blood cancer), bone marrow ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Otrexup
Otrexup is used for polyarticular juvenile idiopathic arthritis, psoriasis, rheumatoid arthritis
Ponatinib
Ponatinib is used to treat chronic myeloid leukemia and Philadelphia chromosome positive acute ...
Mercaptopurine
Mercaptopurine is used for acute lymphoblastic leukemia, autoimmune hepatitis, crohn's disease ...
Dasatinib
Dasatinib is used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML) ...
Doxorubicin
Doxorubicin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
More about Blincyto (blinatumomab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: bispecific T-cell engagers (BiTE)
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.